|
|||||
|
|
Efficacy and safety of MK‐1293 insulin glargine compared with originator insulin glargine (Lantus) in type 1 diabetes: A randomized,open‐label clinical trial |
|
| Authors: | Philip D. Home DPhil Raymond L. H. Lam PhD Wendy L. Carofano PharmD Gregory T. Golm PhD Roy Eldor MD Michael F. Crutchlow MD Michael C. Marcos MS Julio Rosenstock MD Priscilla A. Hollander MD Baptist Gallwitz MD |
| Affiliation: | 1. Newcastle University, Newcastle upon Tyne, UK;2. Merck & Co., Inc., Kenilworth, New Jersey;3. Dallas Diabetes Research Center at Medical City, Dallas, Texas;4. Baylor Endocrine Center, Dallas, Texas;5. University of Tübingen, Tübingen, Germany |
| Abstract: | |
| Keywords: | biosimilar insulin insulin glargine MK‐1293 type 1 diabetes |